AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
[More]
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
[More]
Children with high levels of exposure to bisphenol A are at increased risk for low-grade albuminuria, report researchers.
[More]
Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.
[More]
Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.
[More]
Screening African Americans for microalbuminuria at either 5- or 10-year intervals would be highly cost-effective using a modified version of the CKD Health Policy Model, US researchers report.
[More]
NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease.
[More]
Regardless of age, estimated glomerular filtration rate and high albuminuria are linked to death and end-stage renal disease, say US scientists who found a lower relative but higher absolute mortality risk difference at older age.
[More]
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.
[More]
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium found that chronic kidney disease and its complications were associated with a higher risk of death regardless of age.
[More]
Urinary adiponectin may provide a novel biomarker for diabetic nephropathy, shows research from Finland.
[More]
Urinary adiponectin may provide a novel biomarker for diabetic nephropathy, shows research from Finland.
[More]
NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.
[More]
Young men with low levels of aerobic fitness are more likely to have albuminuria or glomerular hyperfiltration, both early signs of chronic kidney disease, than those with higher levels of fitness.
[More]
Estimated glomerular filtration rate and albumin-creatinine ratio are independently associated with venous thromboembolism, research suggests.
[More]
Estimated glomerular filtration rate and albumin-creatinine ratio are independently associated with venous thromboembolism, research suggests.
[More]
In individuals with type 2 diabetes, any degree of measurable urinary protein excretion—even in what is considered the normal range—increases their risk of experiencing heart problems, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).
[More]
NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.
[More]
A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.
[More]
Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.
[More]